CATALYST PHARMACEUTICALS INC (CPRX)
US14888U1016 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 310.41M | 137.64M | 298.40M | 171.40M | 130.20M | |||
| Marketable Securities | N/A | N/A | 0.00 | 19.80M | 10.00M | |||
| Receivables | 60.49M | 53.51M | 10.40M | 6.60M | 6.00M | |||
| Inventories | 19.95M | 15.64M | 6.80M | 7.90M | 4.70M | |||
| Other Current Assets | 13.74M | 12.54M | 5.20M | 4.30M | 8.30M | |||
| Total Current Assets | 404.60M | 219.33M | 320.80M | 210.10M | 159.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.75M | 3.70M | 3.60M | 4.00M | 100.00K | |||
| Investments And Advances | 15.35M | 16.49M | N/A | N/A | N/A | |||
| Intangibles | 184.71M | 194.05M | 32.50M | N/A | N/A | |||
| Other Non-Current Assets | 38.28M | 36.54M | 18.70M | 23.70M | 33.00M | |||
| Total Non-Current Assets | 242.07M | 250.78M | 54.80M | 27.70M | 33.20M | |||
| TOTAL ASSETS | 646.68M | 470.11M | 375.60M | 237.80M | 192.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 49.13M | 47.53M | 31.50M | 24.00M | 18.10M | |||
| Accounts Payable | 10.26M | 14.79M | 4.00M | 2.80M | 4.30M | |||
| Other Current Liabilities | 20.18M | 13.73M | 22.10M | 300.00K | 400.00K | |||
| Total Current Liabilities | 79.57M | 76.06M | 57.60M | 27.10M | 22.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 5.70M | 6.17M | 17.60M | 3.90M | 0.00 | |||
| Total Non-Current Liabilities | 5.70M | 6.17M | 17.60M | 3.90M | 0.00 | |||
| TOTAL LIABILITIES | 85.26M | 82.23M | 75.20M | 31.00M | 22.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 144.55M | 121.27M | 49.90M | -26.30M | -53.70M | |||
| Additional Paid In Capital | 416.75M | 266.49M | 250.40M | 233.20M | 223.20M | |||
| Common Shares | 118.00K | 107.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | 0.00 | 14.00K | 0.00 | -100.00K | 0.00 | |||
| Shares Outstanding | 118.03M | 107.12M | 105.30M | 103.00M | 103.80M | |||
| Tangible Book Value per Share | 3.19 | 1.81 | 2.54 | 2.01 | 1.63 | |||
| Total Shareholders' Equity | 561.41M | 387.88M | 300.40M | 206.80M | 169.60M | |||
| TOTAL LIABILITIES AND EQUITY | 646.68M | 470.11M | 375.60M | 237.80M | 192.40M | |||
| Statistics | ||||||||
| Current Ratio | 5.09 | 2.88 | 5.57 | 7.75 | 6.98 | |||
| Return On Assets (ROA) | 10.07% | 15.19% | 22.12% | 16.61% | 38.98% | |||
| Return On Equity (ROE) | 11.60% | 18.41% | 27.66% | 19.10% | 44.22% | |||
| Return On Invested Capital (ROIC) | 10.70% | 17.07% | 24.80% | 19.26% | 18.86% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 23.63% | 26.23% | 402.34% | 208.16% | 108.82% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 84.27% | 107.83% | N/A | 208.16% | 108.82% | |||
All data in USD